Amol  Chaubal net worth and biography

Amol Chaubal Biography and Net Worth

CFO of Quanterix
MR. Amol Chaubal serves as Chief Financial Officer of the Company. Prior to joining us, Mr. Chaubal served as the CFO of Global Operations at Smith & Nephew, a global medical devices company, from October 2017 to April 2019. Prior to his time at Smith & Nephew, he served as Corporate Vice President and Head of Finance for the Clinical Research Services business at Parexel from June 2015 to October 2017. Between May 2013 and May 2015, Mr. Chaubal served as CFO North America and Regional Chief Operating Officer at Brookfield Renewable Energy Group, which is part of Brookfield Asset Management. Prior to joining Brookfield, Mr. Chaubal was CFO North America at Novartis AG, where he spent 11 years in positions of increasing responsibility across Switzerland, Canada, and the United States. He has an M.B.A. (with distinction) from INSEAD (France). He began his career at Procter & Gamble Company after completing Masters degree in Chemical Engineering from the Indian Institute of Technology, Mumbai.

What is Amol Chaubal's net worth?

The estimated net worth of Amol Chaubal is at least $614,491.92 as of May 1st, 2020. Mr. Chaubal owns 26,082 shares of Quanterix stock worth more than $614,492 as of March 28th. This net worth evaluation does not reflect any other investments that Mr. Chaubal may own. Learn More about Amol Chaubal's net worth.

How do I contact Amol Chaubal?

The corporate mailing address for Mr. Chaubal and other Quanterix executives is 900 MIDDLESEX TURNPIKE, BILLERICA MA, 01821. Quanterix can also be reached via phone at (617) 301-9400 and via email at [email protected]. Learn More on Amol Chaubal's contact information.

Has Amol Chaubal been buying or selling shares of Quanterix?

Amol Chaubal has not been actively trading shares of Quanterix during the last ninety days. Most recently, Amol Chaubal sold 178 shares of the business's stock in a transaction on Monday, May 3rd. The shares were sold at an average price of $57.86, for a transaction totalling $10,299.08. Learn More on Amol Chaubal's trading history.

Who are Quanterix's active insiders?

Quanterix's insider roster includes Amol Chaubal (CFO), Marijn Dekkers (Director), David Duffy (SVP), John Fry (General Counsel), E Hrusovsky (CEO), Dawn Mattoon (VP), and Mark Roskey (SVP). Learn More on Quanterix's active insiders.

Are insiders buying or selling shares of Quanterix?

During the last year, Quanterix insiders bought shares 1 times. They purchased a total of 20,200 shares worth more than $501,970.00. During the last year, insiders at the sold shares 1 times. They sold a total of 1,500 shares worth more than $36,525.00. The most recent insider tranaction occured on February, 14th when Director Laurie J Olson sold 1,500 shares worth more than $36,525.00. Insiders at Quanterix own 6.8% of the company. Learn More about insider trades at Quanterix.

Information on this page was last updated on 2/14/2024.

Amol Chaubal Insider Trading History at Quanterix

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/3/2021Sell178$57.86$10,299.08View SEC Filing Icon  
4/1/2021Sell165$62.52$10,315.80View SEC Filing Icon  
2/1/2021Sell133$68.26$9,078.58View SEC Filing Icon  
1/5/2021Sell124$44.13$5,472.12View SEC Filing Icon  
12/1/2020Sell115$43.75$5,031.25View SEC Filing Icon  
11/2/2020Sell116$36.97$4,288.52View SEC Filing Icon  
9/1/2020Sell120$34.91$4,189.20View SEC Filing Icon  
8/3/2020Sell114$32.26$3,677.64View SEC Filing Icon  
6/1/2020Sell118$27.32$3,223.7626,082View SEC Filing Icon  
5/1/2020Sell120$25.44$3,052.8026,082View SEC Filing Icon  
4/14/2020Sell1,463$20.34$29,757.4226,082View SEC Filing Icon  
See Full Table

Amol Chaubal Buying and Selling Activity at Quanterix

This chart shows Amol Chaubal's buying and selling at Quanterix by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Quanterix Company Overview

Quanterix logo
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Read More

Today's Range

Now: $23.56
Low: $22.64
High: $23.94

50 Day Range

MA: $24.78
Low: $21.90
High: $28.28

2 Week Range

Now: $23.56
Low: $10.30
High: $29.70

Volume

414,951 shs

Average Volume

337,088 shs

Market Capitalization

$896.69 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31